Novo Nordisk Strikes €1.17 Billion Nanexa Drug Delivery Deal 
FDA Approves Mirum’s Atebrioz for Rare Bone Disorder FOP 
U.S. Dollar Hits Two-Month High as Oil, Treasury Yields Surge 
EQT Plans €1.7 Billion Sale of Parques Reunidos Stake 
Meta Found Liable in New Mexico Facebook Data Privacy Case 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
US Comfortable With Canada Trade Standoff as Import Bans Loom 
China’s ‘Lipstick King’ Says AI Won’t Replace Livestream Hosts 
Akamai Shares Surge on $11.6B Anthropic AI Cloud Deal 
Oracle Shares Fall as New Mexico AI Data Center Faces Power Delays 
Oil Prices Ease as Iran Tensions Clash With Diplomacy Hopes 
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
Oil Prices Jump 3% as Houthi Attack Revives Supply Fears 
Suzuki Targets Faster Car Development to Keep Pace With Chinese Rivals 
Add as a preferred source on Google
US pharmaceutical giant Eli Lilly would cut the cost of its insulin by 70 percent through a series of steps, such as capping out-of-pocket costs at $35 per month for people with insurance.
However, while the US$35 cap takes effect immediately, other measures will be implemented later in the year.
According to the Indianapolis-based Lilly, they are taking actions to make it easier for Americans to access their insulin and help those having ”difficulty navigating a complex healthcare system."
US president Joe Biden called on other pharmaceutical firms to follow suit, noting that it's “flat wrong” to force Americans to pay over $300 for insulin, which costs less than $10 to make.
A centerpiece is the 70 percent price drop in Humalog, Lilly's most commonly prescribed insulin.
According to a 2020 Rand Corporation study, Insulin prices in the US have soared 8 times more than in 32 comparable high-income countries.
But much of the bounty from lofty prices do not go to pharma firms but is passed on to health insurers in the form of rebates.
